CF3-MQC

PubChem CID

• 11713371

ChemSpider

• 9888092

FormulaC₂₉H₂₅F₃N₂O₄

Molar mass522.524 g·mol⁻¹

CF3-MQC

Identifiers
IUPAC name 2-methyl-N-(2-methylphenyl)-5-oxo-4-[5-[2-(trifluoromethoxy)phenyl]furan-2-yl]-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide
PubChem CID	11713371
ChemSpider	9888092
Chemical and physical data
Formula	C29H25F3N2O4
Molar mass	522.524 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC=CC=C1NC(=O)C2=C(NC3=C(C2C4=CC=C(O4)C5=CC=CC=C5OC(F)(F)F)C(=O)CCC3)C
InChI InChI=1S/C29H25F3N2O4/c1-16-8-3-5-10-19(16)34-28(36)25-17(2)33-20-11-7-12-21(35)26(20)27(25)24-15-14-22(37-24)18-9-4-6-13-23(18)38-29(30,31)32/h3-6,8-10,13-15,27,33H,7,11-12H2,1-2H3,(H,34,36) Key:UZXHFTMRTRONRF-UHFFFAOYSA-N

CF3-MQC is an experimental drug developed by Arena Pharmaceuticals, which acts as a reasonably potent and highly selective antagonist for the free fatty acid receptor FFAR3 (GPR41), and is used for research into the function of this receptor.^[1][2][3] It is unclear whether CF3-MQC is the same compound as AR399519, the only other synthetic FFAR3 antagonist currently available, as while they are both cited to the same 2006 patent which claims only six closely related example structures as FFAR3 antagonists,^[4] the structure of AR399519 is not disclosed in the published sources.^[5][6]